MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

Search

Cogent Biosciences Inc

Abrir

7.12 -2.33

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7.07

Máximo

7.47

Indicadores-chave

By Trading Economics

Rendimento

-4.1M

-72M

EPS

-0.525

Funcionários

205

EBITDA

-1.2M

-74M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+133.38% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

192M

827M

Abertura anterior

9.45

Fecho anterior

7.12

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de jun. de 2025, 21:26 UTC

Grandes Movimentos do Mercado

AeroVironment Shares Slide on Stock, Notes Offerings

30 de jun. de 2025, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Won't Withdraw Sabadell Offer

30 de jun. de 2025, 23:43 UTC

Conversa de Mercado

Gold Edges Higher, Underpinned by Fed-Rate Cut Hopes -- Market Talk

30 de jun. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Fall as Yen Has Strengthened Amid Trade Uncertainty -- Market Talk

30 de jun. de 2025, 23:38 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de jun. de 2025, 23:03 UTC

Ganhos

Boeing CFO Exit Is Latest Change in Chief Executive Kelly Ortberg's C-Suite -- Update

30 de jun. de 2025, 22:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Giant Eagle Closes Sale of Its GetGo Business to Alimentation Couche-Tard

30 de jun. de 2025, 22:50 UTC

Ganhos

Boeing Hires Former Lockheed Martin Executive to Succeed CFO Brian West -- Update

30 de jun. de 2025, 21:26 UTC

Ganhos

Berkshire Stock Ends Quarter on Sour Note. It's About Even With S&P 500 So Far in 2025. -- Barrons.com

30 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

30 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

30 de jun. de 2025, 19:46 UTC

Conversa de Mercado

Nike's Buzz is Back Amid Lean into Women Sports -- Market Talk

30 de jun. de 2025, 19:16 UTC

Conversa de Mercado

Oil Futures Snap Winning Streak on OPEC+ Outlook -- Market Talk

30 de jun. de 2025, 19:10 UTC

Conversa de Mercado

U.S. Natural Gas Wipes Out Friday's Gains -- Market Talk

30 de jun. de 2025, 19:07 UTC

Conversa de Mercado

Dollar Ends Losing Quarter Facing Downward Pressure -- Market Talk

30 de jun. de 2025, 18:27 UTC

Conversa de Mercado

Gold Has Largest Half-Year Gain Since 2007 -- Market Talk

30 de jun. de 2025, 17:08 UTC

Aquisições, Fusões, Aquisições de Empresas

MicroStrategy Stock Jumps After Latest Bitcoin Purchase as Holdings Near 600,000 Tokens -- Barrons.com

30 de jun. de 2025, 17:00 UTC

Aquisições, Fusões, Aquisições de Empresas

HPE Stock Soars as Juniper Merger Gets Regulatory Approval. There's Just 1 Catch. -- Barrons.com

30 de jun. de 2025, 16:41 UTC

Conversa de Mercado

WTI Crude Undeperforms as U.S.-Canada Trade Talks to Resume -- Market Talk

30 de jun. de 2025, 16:32 UTC

Conversa de Mercado

United Parks' Potential Buyback Resumption Could Be Catalyst For Stock -- Market Talk

30 de jun. de 2025, 16:23 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA: Offer Remains in Effect in Accordance With Applicable Regulations

30 de jun. de 2025, 16:22 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Decided Not to Withdraw Offer for Banco De Sabadell

30 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

30 de jun. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

30 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

30 de jun. de 2025, 16:07 UTC

Ganhos

Umicore to Post 1H Results on Aug 1

30 de jun. de 2025, 15:59 UTC

Conversa de Mercado

Copper Conditions Set to Remain Tight But Risks Loom -- Market Talk

30 de jun. de 2025, 15:55 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Home Depot to Consolidate Pro Distribution with GMS Deal -- Market Talk

30 de jun. de 2025, 15:54 UTC

Conversa de Mercado

Gold Futures Recoup Some Losses Though Demand Looks Set to Weaken -- Market Talk

30 de jun. de 2025, 15:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Google Bets Big on Nuclear Fusion With MIT Spinoff Commonwealth -- Barrons.com

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

133.38% parte superior

Previsão para 12 meses

Média 16.57 USD  133.38%

Máximo 25 USD

Mínimo 7 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

7

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.88 / 5.87Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.